Search
Jazz Pharmaceuticals PLC
JAZZAdd to Watchlist
224.660USD
-2.270-1.00%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
14.11BMarket Cap
544.84P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Jazz Pharmaceuticals PLC is 8.67, ranking 13 out of 157 in the Pharmaceuticals industry. The average price target is 210.00, with a high of 247.00 and a low of 147.00.
Analyst Rating
Based on
19
analysts
Buy
Current Rating
258.275
Target Price
+13.81%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Jazz Pharmaceuticals PLC
JAZZ
19
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Jazz Pharmaceuticals PLC's expected revenue for the next quarter?
Jazz Pharmaceuticals PLC's expected revenue is 1.11B.
What is Jazz Pharmaceuticals PLC's price target?
Analysts forecast that Jazz Pharmaceuticals PLC's price target is USD 210.00, with the highest forecast at USD 247.00 and the lowest forecast at USD 147.00.
How have Jazz Pharmaceuticals PLCJAZZ's recent earnings per share performed?
The market expectation was USD 4.74, while Jazz Pharmaceuticals PLCJAZZ's earnings per share (EPS) for the previous quarter was USD 3.33. EPS for the next quarter is expected at USD 6.18.
What is the analyst rating for Jazz Pharmaceuticals PLC?
Based on the ratings of Jazz Pharmaceuticals PLC's stock from 19 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
